Speakers - Sachs Associates

CONTACT
Willem van Weperen
Chief Executive Officer
ADDRESS
Niels Bohrweg 11
2333 CA Leiden
The Netherlands
TELEPHONE
+31 71 332 2252
FAX
+31 84 831 3409
EMAIL
vanweperen@tobbb.com
YEAR FOUNDED
2004
to-BBB technologies
www.tobbb.com
FINANCIAL SUMMARY
Seed 2004-2006: ±€1M
Series-A 2007: ±€4M
Series-B 2011: ±€6M
Accum grants/credits: ±€5M
COMPANY PROFILE
to-BBB is a clinical stage blood-brain barrier company in the Netherlands with a proprietary technology
(G-Technology®) to safely enhance brain drug delivery. The company is performing a phase I/II study with lead
product 2B3-101, which focuses on brain metastases of Breast Cancer and glioblastoma.
to-BBB is also developing 2B3-201 for neuroinflammation in MS, neuropathic pain and ALS, which will be in the
clinic in 2013. Furthermore, the company is exploring additional product propositions in stroke, Alzheimer’s and
orphan brain diseases.
The business model of to-BBB is based on partnerships with pharma/biotech companies. The company has
entered into several research collaborations with academic and pharma partners on brain drug delivery.
In 2011 to-BBB completed a series-B round of ±€6M and over the years the company generated substantial
non-dilutive funding. The company expects to be cash positive based on license income after a last equity round
in 2013.
MANAGEMENT
Willem van Weperen, MSc, MBA, Chief Executive Officer
Pieter Gaillard, PhD, Chief Scientific Officer/founder:
Fredrik Lonnqvist, MD, PhD, Assoc. Prof., Chief Medical Officer
t back :: next u
WELCOME PHARMA LICENSING GROUPS
SPEAKERS
PRESENTING COMPANIES SUPPORTING ORGANISATIONS
ORGANISERS